CD300LF and neoplasm: Ceramides may be obstructing Th1 cell responses by activating the myeloid cell receptor CD300f, as the inhibition of CD300f promoted dendritic-cell-initiated Th1 responses when enhancing the anti-tumour effect of immunisation in a mouse model [15].